Losartan – more than blood pressure decrease
Authors:
J. Špinar; J. Vítovec
Published in the journal:
Kardiol Rev Int Med 2006, 8(3): 115-120
Category:
Editorial
Summary
Losartan is a long acting AT1 receptor blocker, which is widely used in the United States and Europe including Czech Republic. Its effectivity was proved in heart failure (ELITE II), after myocardial infarction (OPTIMAAL), in diabetic nephropathy (RENAAL), but especially in hypertension (LIFE). The treatment with losartan, when compared with atenolol led to a similar blood pressure fall, but with a greater effect on stroke, new diabetes mellitus or left ventricle regression in the LIFE trial. New data from this trial show, that the treatment with losartan was also accompanied with a lower incidence of atrial fibrillation, better control of known atrial fibrillation, improvement in insulin sensitivity, lower incidence of microalbuminuria and many other positive results.
Key words:
losartan, hypertension, diabetes mellitus, insulin sensitivity, nephropathy, atrial fibrillation
Zdroje
1.American Diabetes Association. Diabetic Nefropathy. Diabetes Care 2002; 25 (Supp 1): 85-89.
2.Brenner BM, Cooper ME, Zeeuw D for the RENAAL investigators. RENAAL: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
3.Cífková R, Horký K, Widimský J sr et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2004; 50: 709-722.
4.Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
5.Dewereux RB, Dahlof B, Kjeldsen SE et al. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy if the LIFE randomised trial. Ann Intern Med 2003; 139: 169-177.
6.Dewereux RB, Wachtel K, Gerds E et al. Prognostic significance of left ventricula mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
7.Dickstein K, Kjekshus J and OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL ransomised trial. Lancet 2002; 360: 752-760.
8.Fossum E, Olsen MH, Hoieggen A et al. Long-rem plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS a LIFE substudy. J Hum Hypertens 2004; 18: 375-380.
9.Fyhrquist F, Dahlof B, Devereaux RB et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricle hypertrophy. Hypertension 2005; 45: 580-585.
10.Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1048.
11.Kjeldsen SE, Dahlof RB, Julius S et al. Effect of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left vetricle hypertrophy: a Losartan intervention for Endpoint reduction (LIFE) study. JAMA 2002; 288: 1491-1498.
12.Kjeldsen SE, Lyle PA, Kizer JR et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricle hypertrophy. The LIFE study. J Clin Hypertens 2005; 7: 152-158.
13.Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from LIFE study. Lancet 2003; 362: 19-20.
14.Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity nad mortality in patients with diabetes in the Losartan Intervention for Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
15.Olsen MH, Fossum E, Hoieggen A et al. Long term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23: 891-898.
16.Olsen MH, Wachtel K, Tuxen C et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricle hypertrophy: a LIFE substudy. J Hypertens 2005; 23: 1083-1090.
17.Pitt B, Poole-Wilson PA, Segal R et al on behalf of the ELITE II Investigators: ELITE II (Effects of Losartan Versus Captopril on Mortality in Patients With Symptomatic Heart Failure). Lancet 2000; 355: 1582-1587.
18.Poulter NR for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rate noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913.
19.Špinar J, Vítovec J. AII antagonisté vytáhli trumfové eso – studie LIFE a SCOPE. Cor Vasa 2002; 44: 537-540.
20.Vítovec J, Špinar J. Antagonisté receptoru AT1 pro angiotenzin II(ARB) v léčbě hypertenze STUDIE LIFE. Klin Farmakol Farm 2003; 17: 43-45.
21.Vítovec J, Špinar J. Mohou blokátory receptorů pro angiotenzin II (AIIA) nahradit v léčbě srdečního selhání inhibitory ACE? Cor Vasa 2003; 45: 169-170.
22.Yin Y, Dalal D, Liu Z et al. Prospective randomised study comparing amiodarone vs amiodarone plus losartan vs amiodarone plus perindopril for the prevention of atrial fibrillation in patients with lone paroxysmal atrial fibrillation. EHJ 2006; 27: 1841-1846.
23.Wachtel K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705-711.
24.Wachtel K, Lehto M, Gerdts E et al. Angiotensin II receptor blocker reduces new oncet atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
25.Zanchetti A for the guidelines committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1023.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2006 Číslo 3
Najčítanejšie v tomto čísle
- Non-invasive examination in arterial hypertension
- Losartan – more than blood pressure decrease
- Remote monitoring of implantable pacemakers and cardioverters-defibrillators
- Treatment of diabetes mellitus in cardiac patients